Lund (Sweden) - December 3, 2012. NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion® in the scientific journal Clinical Drug Investigation. The pa ...

Beijing (China) and Lund (Sweden) - November 20, 2012. NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. f ...

Note: This is an English version of a press release communicated by NeuroVive 2012-10-08 Ongar (UK) and Lund (Sweden) - 8 October, 2012. UK-based Mitopharm Limited, a subsidiary of Selcia Holdings Lim ...

Lund, Sweden, 15 December 2011

Lund, Sweden / Leiden, the Netherlands, 29 September 2011 NeuroVive Pharmaceutical AB (publ) and to-BBB, the Dutch brain drug delivery company, have been awarded a grant of €1 million through the Eure ...

Ongar (UK) and Lund (Sweden), September 19, 2011 - UK-based contract research organisation Selcia Limited and Swedish drug development company NeuroVive Pharmaceutical AB (publ) have signed a signific ...

Lund, Sweden - September 15, 2011 - A U.S. magazine called Pharmaceutical Formulation & Quality (circulation to 20,000 senior pharmaceutical executives throughout the US and Canada) has just published ...

Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue

Note: This is an English version of a press release communicated by NeuroVive 2011-03-02 Phase II/III study will determine the safety and efficacy of NeuroSTAT® in patients with moderate to severe tra ...

Note: This is an English version of a press release communicated by NeuroVive 2010-12-01 December 6, 2010 - Lund, Sweden. NeuroVive Pharmaceutical AB (NVP) announces that the U.S. FDA Office of Orphan ...

Note: This is an English version of a press release communicated by NeuroVive 2010-10-25 NeuroVive Pharmaceutical and to-BBB, the Dutch drug brain delivery company, are entering into a joint program t ...